Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Galderma Group AG (GALD)
Track the Galderma share price today and view real-time GALD share price data, including charts, technicals, and key financials. View the GALD premarket stock price ahead of the market session or assess the after hours quote. Explore GALD stock price movements, trading volume, and market activity across the SIX exchange.
What Is the Galderma Stock Price Today?
The Galderma stock price today is 189.00.
What Is the Stock Symbol for Galderma?
The stock symbol for Galderma is ""GALD.""
What Stock Exchange Does Galderma Trade On?
Galderma is listed and trades on the Switzerland stock exchange.
Is Galderma a Good Stock to Buy?
Determining whether Galderma or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GALD quote. (ISIN: CH1335392721)
What Is the Galderma Stock Price Today?
The Galderma stock price today is 189.00.
What Is the Stock Symbol for Galderma?
The stock symbol for Galderma is ""GALD.""
What Stock Exchange Does Galderma Trade On?
Galderma is listed and trades on the Switzerland stock exchange.
Is Galderma a Good Stock to Buy?
Determining whether Galderma or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GALD quote. (ISIN: CH1335392721)
Currency in CHF
189.00
-2.50(-1.31%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
187.20
191.10
52 wk Range
136.30
193.90
GALD is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
187.20191.10
52 wk Range
136.30193.90
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
GALD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
204.06
Upside
+7.97%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
Galderma receives Investment Bank Analyst Rating Update- Investing.com
Pro- Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Galderma receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Galderma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
14 Buy
2 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 204.06
(+7.97% Upside)
Galderma Group AG Earnings Call Summary for Q3/2026
- Galderma posted Q3 revenue of $1.63B, beating estimates by 5.16%, and raised 2026 sales growth guidance to 22.5%-23.5% from 19%-21%.
- Nine-month net sales hit record $4.765B, up 25.1% at constant currency, driven by Nemluvio which generated over $300M in Q3 alone.
- Stock surged 7.23% to $186.85 in premarket trading, approaching 52-week high of $188.25 on strong results and improved outlook.
- ZO Skin Health acquisition expected to close Q4 2026 or early 2027; management cautioned 2027 will be a 'year of reset' for integration.
- Core EBITDA margin guidance held at 26% as company prioritizes growth investment; Relfydess U.S. resubmission targeted for Q1 2027.
Last Updated: 23/10/2026, 01:36 am
Read Full TranscriptEarnings
Latest Release
22/10/2026
EPS / Forecast
-- / 1.03
Revenue / Forecast
1.63B / 1.55B
Compare GALD to Peers and Sector
Metrics to compare | GALD | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipGALDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 62.4x | 31.3x | −0.2x | |
PEG Ratio | 0.48 | −0.42 | 0.00 | |
Price/Book | 6.6x | 5.5x | 2.6x | |
Price / LTM Sales | 9.1x | 5.3x | 2.8x | |
Upside (Analyst Target) | 8.3% | −4.1% | 65.5% | |
Fair Value Upside | Unlock | 1.6% | 8.9% | Unlock |
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Galderma (GALD) Stock Price Today?
The Galderma stock price today is 189.00 CHF.
What Stock Exchange Does Galderma Trade On?
Galderma is listed and trades on the Switzerland Stock Exchange.
What Is the Stock Symbol for Galderma?
The stock symbol for Galderma is "GALD."
Does Galderma Pay Dividends? What’s The Current Dividend Yield?
The Galderma dividend yield is 0.2%%.
What Is the Galderma Market Cap?
As of today, Galderma market cap is 44.07B CHF.
What Is Galderma's Earnings Per Share (TTM)?
The Galderma EPS (TTM) is 2.98.
When Is the Next Galderma Earnings Date?
Galderma will release its next earnings report on 11/03/2027.
From a Technical Analysis Perspective, Is GALD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Galderma Stock Split?
Galderma has split 0 times.
How Many Employees Does Galderma Have?
Galderma has 7676 employees.
What is the current trading status of Galderma (GALD)?
As of 03/11/2026, Galderma (GALD) is trading at a price of 189.00 CHF, with a previous close of 189.00 CHF. The stock has fluctuated within a day range of 187.20 CHF to 191.10 CHF, while its 52-week range spans from 136.30 CHF to 193.90 CHF.
What Is Galderma (GALD) Price Target According to Analysts?
The average 12-month price target for Galderma is 204.06 CHF, with a high estimate of 263.2296681 CHF and a low estimate of 134.13570826 CHF. 14 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +7.97% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.